Guideline / position statementindependent cross-checkabstract only checked I-GUT-01 standard review
Maastricht VI: H. pylori management
Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report.
Overview
Malfertheiner P et al.. Gut 2022 · PMID 35944925 · DOI 10.1136/gutjnl-2022-327745
H. pylori is an infectious disease; infected people should be treated.
Does the study support the specific claim? No · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
H. pylori guidance.
- How was the study done?
Consensus.
- What was actually found?
Treat all infected.
- What do the results mean in everyday life?
Treatment is standard.
- What are the study's limitations?
Consensus; COI.
- What does it say about Elawady's specific claim?
Contradicts C-GUT-06.
- Do the results apply to Germany and Europe?
European.
Scientific in-depth review
1. Full reference
- Authors
- Malfertheiner P et al.
- Journal
- Gut
- Year
- 2022
- Identifier
- PMID 35944925 DOI 10.1136/gutjnl-2022-327745
- Verification
- verified – PubMed efetch 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
Competing interests: PM has served as speaker, advisory board member and consultant for Bayer, Biohit, Biocodex, Danone, Mayoly, Malesci, Menarini and Phathom Pharamaceuticals. JPG has served as speaker, consultant, and advisory member for or has received research funding from Mayoly, Allergan, Diasorin, Gebro Pharma, and Richen. Moss is a consultant for Takeda and Phathom Pharmaceuticals and has received. research support from American Molecular Laboratories. Rajilic-Stojanovic has served as speaker and advisory board member for Abela Pharm DOO and Adoc DOO. Dinis- Ribeiro has serveds as speaker and advisory board member for Medtronic, Roche Consultancy and Fujifilm. Lanas participates in Advisory Boards to Bayer A.G. and Glaxo-SKF.
2. Research question
Management of H. pylori infection
3. Study design and population
- Study design
- Guideline / position statement – International consensus report (Maastricht VI/Florence)
- Population
Global
- Country
Multinational (41 experts, 29 countries)
- Period
2021–2022
4. Methods and endpoints
- Endpoints
Consensus statements
- Statistical methods
Consensus voting
5. Actual results
- Results
H. pylori infection is recognised as an infectious disease (ICD-11); recommendation that all infected patients should receive treatment; addresses gastric cancer prevention and rising antibiotic resistance.
- Absolute risks
not applicable
- Authors' conclusion
Recommendations on indications, diagnosis, treatment, prevention, microbiota.
6. Strengths
- Global consensus
7. Weaknesses
- Industry COI of several authors
- Abstract only read
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Consensus.
9. Assessment of the statistical interpretation
10. Relevance to the specific claim
11. Independent contrary findings
12. Transferability to Germany and Europe
European consensus.
13. Overall methodological judgement
Standard of care.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | not assessable |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | unknown |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
15. Linked fact checks
- Redefining peptic ulcer as an H. pylori infection was a 'crime'; the real problem is low stomach acid, and acid blockers plus antibiotic 'triple therapy' are the wrong treatment. – Studies contradicting or limiting the claim
- The common test for H. pylori ('the stomach germ') is the test with the highest rate of false-positive results. – Studies contradicting or limiting the claim